DICOTnews May 2026
Dicot Pharma is well positioned to take the next step in our value creation journey. Preparations for the planned Phase 2b study are progressing at full speed, while there is also strong momentum on the financial side, where we are seeing significant interest in the rights issue that has just been launched. The energy in the company is clear: full speed ahead!
Elin Trampe, CEO of Dicot Pharma
Rights issue in progress
The subscription period for our rights issue is now open! As of today, SEK 168 million has already been secured, corresponding to full financing of the planned Phase 2b study. Existing shareholders have preferential rights to subscribe in the issue.
Company presentation and Q&A
In connection with the rights issue, we are hosting a digital company presentation and Q&A session in Swedish with CEO Elin Trampe and CFO Björn Petersson on 27 May at 12:00 CEST. Questions can be submitted in advance to [email protected].
IND submitted to the FDA
Our Phase 2b study is expected to start in the second half of this year, and preparations are well underway. We have now submitted a so-called IND to the FDA, to obtain clearance to initiate the study in the United States.
Tablets manufactured
The manufacturing of the tablets to be used in the planned Phase 2b study was recently completed. This marks another important step in the preparations ahead of study start, finalized according to plan.
Q1 – in words and images
The first quarter of the year was characterized by strong momentum and energy, with continued focus on value creation in line with our clinical and strategic agenda. Read more about this in the report and watch the interview published shortly after its release.
Article in Pharma Vanguard
Pharma Vanguard is a well-regarded publication focused on clinical trials. In an article titled “How Dicot Pharma Is Rethinking Erectile Dysfunction from the Ground Up”, journalist Moe Alsumidaie shares his view of our business.
Elin joins LSX panel
During the LSX World Congress, Elin Trampe was invited to take part in the panel discussion “Early Commercial Strategy: Building Value from Day One”, where she shared her insights on the importance of integrating commercial strategy early in pharmaceutical development.
Presenting the 2025 Annual Report
The 2025 Annual Report was published on 9 April. As always, it´s filled with articles, figures and facts from the year, including interviews with Chairman of the Board Eva Sjökvist Saers and sexual medicine expert Dr Harin Padma-Nathan.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.